Back to Search
Start Over
Assessment of Bone Mineral Density Over 1 Year in a Cross-Sectional Cohort of Migraine Patients Receiving Anti-CGRP Monoclonal Antibodies.
- Source :
-
CNS drugs [CNS Drugs] 2024 Oct; Vol. 38 (10), pp. 819-825. Date of Electronic Publication: 2024 Aug 22. - Publication Year :
- 2024
-
Abstract
- Background: Calcitonin gene-related peptide (CGRP), implicated in migraine pain, also possesses bone anabolic properties, which leads to the possibility that monoclonal antibodies targeting CGRP (anti-CGRPs) might increase the risk of bone density abnormalities.<br />Objective: The objective of this study was to explore bone mineral density abnormalities in a cohort of migraine patients treated with anti-CGRPs.<br />Methods: This was a single-center, cross-sectional, cohort study including migraine patients who underwent a densitometry assessment during anti-CGRP treatment. We assessed the frequency of osteopenia or osteoporosis (OSTEO+ status), defined as a bone mineral density T-score of -1 to -2.5, and <-2.5 standard deviations from the young female adult mean, respectively. Additionally, the association of OSTEO+ status with anti-CGRP treatment duration and primary osteoporosis' risk factors was investigated using logistic regression models.<br />Results: Data from 51 patients (43 female, mean age 46 ± 13.9 years) were evaluated. The mean duration of anti-CGRP treatment was 15.7 (±11.8) months. Twenty-seven patients (53%) were OSTEO+ (n = 22 osteopenia; n = 5 osteoporosis). In the final model, menopause [odds ratio 11.641 (95% confidence interval 1.486-91.197), p = 0.019] and anti-seizure drug use [odds ratio 12.825 (95% confidence interval 1.162-141.569), p = 0.037] were associated with OSTEO+ status.<br />Conclusions: In our cohort of migraine patients, no evidence of an association between anti-CGRP treatment duration and an increasing risk of bone mineral density abnormalities was found. However, these findings are preliminary and necessitate further longitudinal research with larger cohorts and extended follow-up to be validated.<br /> (© 2024. The Author(s).)
- Subjects :
- Humans
Female
Cross-Sectional Studies
Middle Aged
Adult
Male
Cohort Studies
Risk Factors
Migraine Disorders drug therapy
Bone Density drug effects
Osteoporosis drug therapy
Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal adverse effects
Antibodies, Monoclonal pharmacology
Antibodies, Monoclonal therapeutic use
Bone Diseases, Metabolic epidemiology
Calcitonin Gene-Related Peptide immunology
Subjects
Details
- Language :
- English
- ISSN :
- 1179-1934
- Volume :
- 38
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- CNS drugs
- Publication Type :
- Academic Journal
- Accession number :
- 39174745
- Full Text :
- https://doi.org/10.1007/s40263-024-01104-0